Genomic signatures to guide the use of chemotherapeutics
- 22 October 2006
- journal article
- retracted article
- Published by Springer Nature in Nature Medicine
- Vol. 12 (11) , 1294-1300
- https://doi.org/10.1038/nm1491
Abstract
Using in vitro drug sensitivity data coupled with Affymetrix microarray data, we developed gene expression signatures that predict sensitivity to individual chemotherapeutic drugs. Each signature was validated with response data from an independent set of cell line studies. We further show that many of these signatures can accurately predict clinical response in individuals treated with these drugs. Notably, signatures developed to predict response to individual agents, when combined, could also predict response to multidrug regimens. Finally, we integrated the chemotherapy response signatures with signatures of oncogenic pathway deregulation to identify new therapeutic strategies that make use of all available drugs. The development of gene expression profiles that can predict response to commonly used cytotoxic agents provides opportunities to better use these drugs, including using them in combination with existing targeted therapies.Keywords
This publication has 24 references indexed in Scilit:
- Clinical Cancer Advances 2005: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical OncologyJournal of Clinical Oncology, 2006
- Why Therapeutic Response May Not Prolong the Life of a Cancer Patient: Selection for Oncogenic ResistanceCell Cycle, 2005
- Association of Pretherapeutic Expression of Chemotherapy-Related Genes with Response to Neoadjuvant Chemotherapy in Barrett CarcinomaClinical Cancer Research, 2005
- Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrationsInternational Journal of Cancer, 2005
- Targeted therapy against Bcl-2-related proteins in breast cancer cellsBreast Cancer Research, 2005
- Cyclin A–associated kinase activity is needed for paclitaxel sensitivityMolecular Cancer Therapeutics, 2005
- Phosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast CancerCancer Investigation, 2005
- Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancerThe Lancet, 2003
- Chemosensitivity prediction by transcriptional profilingProceedings of the National Academy of Sciences, 2001
- Twenty-Two Years of Phase III Trials for Patients With Advanced Non–Small-Cell Lung Cancer: Sobering ResultsJournal of Clinical Oncology, 2001